Dr Igor Puzanov Discusses the State of Adjuvant Therapy for Advanced Melanoma
Source: AJMC, September 2022
In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.
Igor Puzanov, MD, is clinical professor of medicine at the Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, and professor of medicine and director of the Early Phase Clinical Trials Program, Department of Medicine, at Roswell Park Comprehensive Cancer Center.
In this interview with The American Journal of Managed Care® (AJMC®), he discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.